From: Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register
Disease activity at 12 months
BIOL, n (%)
CON, n (%)
In remission (DAS28 <2.6)
56 (54.9%)
18 (58.1%)
Low disease activity (DAS28 <3.2)
17 (16.7%)
7 (22.6%)
Moderate or high disease activity (DAS28 >3.2)
29 (28.4%)
6 (19.4%)
Total
102
31